The importance of metabolic markers in the development of a second ischemic stroke
- 作者: Shishkova V.N1,2, Adasheva T.V2, Stakhovskaya L.V3
-
隶属关系:
- Center for Speech Pathology and Neurorehabilitation, Moscow Healthcare Department
- A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
- N.I. Pirogov Russian National Research Medical University
- 期: 卷 31, 编号 10 (2020)
- 页面: 65-68
- 栏目: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/114313
- DOI: https://doi.org/10.29296/25877305-2020-10-12
- ID: 114313
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
Objective. To investigate the relationship between plasma adiponectin (ADN) levels and the rate of a second noncardioembolic ischemic stroke (IS) over a three-year period Subjects and methods. The cohort observational study covered 206 patients who had experienced a first noncardioembolic IS, explored the clinical and metabolic parameters of the participants, and assessed the frequency and date of onset of a secondary IS using the Cutler-Ederer and Kaplan-Meier methods according to AND concentrations. Fasting plasma ADN concentrations (pg/ml) were determined using the BioVendor kits (Sweden) on a third-generation Reader UNIPLAN-9213 microplate photometer (PIKON, Russia). Results. The analysis of the frequency and date of onset of a second noncardioembolic IS over a three-year period showed an increased risk of its development in patients with low ADN levels (<7 pg/ml). Conclusion. The patients with a low ADN level are at a high risk for a second noncardioembolic IS.
全文:
作者简介
V. Shishkova
Center for Speech Pathology and Neurorehabilitation, Moscow Healthcare Department; A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
Email: veronika-1306@mail.ru
T. Adasheva
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
L. Stakhovskaya
N.I. Pirogov Russian National Research Medical University
参考
- Стаховская Л.В., Котов С.В., Исакова Е.В. Инсульт: руководство для врачей. М.: ООО «Медицинское информационное агентство», 2013; 400 с
- Шишкова В.Н. Механизмы развития сердечно-сосудистых заболеваний и сахарного диабета типа 2: роль инсулинорезистентности, гиперинсулинемии и гипоадипонектинемии. Вопросы коррекции. Системные гипертензии. 2014; 11 (2): 48-53 doi: 10.26442/2075-082X_11.2.48-53
- Arregui M., Buijsse B., Fritsche A. et al. Adiponectin and risk of stroke: prospective study and meta-analysis. Stroke. 2014; 45 (1): 10-7. DOI: 10.1161/ STR0KEAHA.113.001851
- Bang O.Y., Savel J.L., Ovbiagele V. et al. Adiponectin levels in patients with intracranial atherosclerosis. Neurology. 2007; 68 (22): 1931-7. doi: 10.1212/01. wnl.0000263186.20988.9f
- Шишкова В.Н., Адашева Т.В., Ременник А.Ю. и др. Прогностическая значимость клинико-антропометрических, биохимических, метаболических, сосудисто-воспалительных и молекулярно-генетических маркеров в развитии первого ишемического инсульта. Журнал неврол. и психиатр. им. С.С. Корсакова. 2018; 118 (2): 4-11 https://doi.org/10.17116/jnevro2018118214-11
- Dastani Z., Hivert M.F., Timpson N. et al. Novel Loci for Adiponectin Levels and Their Influence on Type 2 Diabetes and Metabolic Traits: A Multi-Ethnic MetaAnalysis of 45,891 Individuals. PLoS. Genet. 2012; 8 (3): e1002607. DOI: 10.1371/ journal.pgen.1002607
- Kawai T., Ohishi M., Takeya Ya. et al. Adiponectin single nucleotide polymorphism is a genetic risk factor for stroke trough high pulse wave pressure: a cohort study. J. Atheroscler Thromb. 2013; 20 (2): 152-60. DOI: 10.5551/ jat.14696
- Chen L., Sun K.X., Juan J. et al. CDH13 genetic polymorphisms, adiponectin and ischemic stroke: a chine family-based sib-pair study. Biomed Environ Sci. 2017; 30 (1): 35-43. doi: 10.3967/bes2017.004
补充文件
